Phage therapy specialist Vésale Bioscience gas bageds €1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Abionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI)
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
Evosep APS has inked a $40m funding deal with Novo Holdings A/S that is aimed to advance standardised clinical LC-MS-based drug discovery and diagnostic multi-marker tests.
With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.